Following the example of the sun, fusion power plants aim to fuse the hydrogen isotopes deuterium and tritium and release large amounts of energy in the process. The only plant in the world currently capable of operating with such fuel is the European joint project JET, the Joint European Torus in Culham near Oxford, UK. However, the last experiments with the fuel for future fusion power plants were conducted there in 1997. Because tritium is a very rare raw material that also poses special handling challenges, research teams usually use hydrogen or deuterium for plasma experiments. In future power plants, tritium will be formed from lithium during energy production.

Experiments with deuterium-tritium mixtures in preparation for ITER

“We can explore the physics in fusion plasmas very well by working with hydrogen or deuterium, so this is the standard worldwide,” explains IPP’s Dr. Athina Kappatou, who with her IPP colleagues Dr. Philip Schneider and Dr. Jörg Hobirk led significant parts of the European collaborative experiments at JET.” However, for the transition to the international, large-scale, fusion experiment ITER, it is important that we prepare for the conditions prevailing there.” ITER is currently under construction in Cadarache, in southern France, and is expected to be able to release ten times as much energy as is fed into the plasma in terms of heating energy, using deuterium-tritium fuel.

To bring the JET experiment as close as possible to future ITER conditions, the previous carbon lining of the plasma vessel was replaced by a mixture of beryllium and tungsten, as is also planned for ITER, between 2009 and 2011. The metal tungsten is more resistant than carbon, which, moreover, stores too much hydrogen. However, the now metallic wall places new demands on the quality of the plasma control. The current experiments demonstrate the successes of the researchers: At temperatures ten times higher than those at the center of the sun, record levels of generated fusion energy have been achieved.

World record under ITER-like conditions

Prior to the change of the wall material, JET had set the world energy record in 1997 with a plasma that produced 22 megajoules of energy. This record stood until now. “In the latest experiments, we wanted to prove that we could create significantly more energy even under ITER-like conditions,” explains IPP physicist Dr. Kappatou. Several hundred scientists and researchers were involved in years of preparation for the experiments. They used theoretical methods to calculate in advance the parameters they needed to obtain to generate the plasma in order to achieve their goals. The experiments confirmed the predictions in late 2021 and delivered a new world record: JET produced stable plasmas with deuterium-tritium fuel that released 59 megajoules of energy.

To produce net energy — that is, to release more energy than the heatering systems provide — the experimental facility is too small. This will not be possible until the larger-scale ITER experiment in southern France comes online. “The latest experiments at JET are an important step toward ITER,” concludes Prof. Sibylle Günter, Scientific Director of the Max Planck Institute for Plasma Physics. “What we have learned in the past months will make it easier for us to plan experiments with fusion plasmas that generate much more energy than is needed to heat them.”

Background information: Megawatts vs. Megajoules

In the recent record-breaking experiment, the fusion reactions in JET released a total of 59 megajoules of energy in the form of neutrons during a five-second phase of a plasma discharge. Expressed in units of power (energy per time), JET achieved a power output of just over 11 megawatts averaged over five seconds. The previous energy record, set in 1997, was just under 22 megajoules of total energy and 4.4 megawatts of power averaged over five seconds.

About JET

JET was jointly designed and built by the members of the European fusion program EUROfusion and has been jointly operated since 1983. The English fusion center “Culham Centre for Fusion Energy” in Culham near Oxford is responsible for the technical operations, while temporarily seconded researchers and technicians from the EUROfusion laboratories work on the facility on a campaign basis. With numerous secondments, IPP is an important participant in the JET program.

About Max Planck Institute for Plasma Physics

The research conducted at the Max Planck Institute for Plasma Physics (IPP) in Germany (locations: Garching near Munich and Greifswald) is concerned with investigating the physical basis of a fusion power plant. Like the sun, such a plant aims to generate energy from fusion of atomic nuclei. IPP’s research is part of the European fusion program. With its workforce of approximately 1,100 IPP is one of the largest fusion research centers in Europe.

“The discovery shows that our closest stellar neighbour seems to be packed with interesting new worlds, within reach of further study and future exploration,” explains João Faria, a researcher at the Instituto de Astrofísica e Ciências do Espaço, Portugal and lead author of the study published today in Astronomy & Astrophysics. Proxima Centauri is the closest star to the Sun, lying just over four light-years away.

The newly discovered planet, named Proxima d, orbits Proxima Centauri at a distance of about four million kilometres, less than a tenth of Mercury’s distance from the Sun. It orbits between the star and the habitable zone — the area around a star where liquid water can exist at the surface of a planet — and takes just five days to complete one orbit around Proxima Centauri.

The star is already known to host two other planets: Proxima b, a planet with a mass comparable to that of Earth that orbits the star every 11 days and is within the habitable zone, and candidate Proxima c, which is on a longer five-year orbit around the star.

Proxima b was discovered a few years ago using the HARPS instrument on ESO’s 3.6-metre telescope. The discovery was confirmed in 2020 when scientists observed the Proxima system with a new instrument on ESO’s VLT that had greater precision, the Echelle SPectrograph for Rocky Exoplanets and Stable Spectroscopic Observations (ESPRESSO). It was during these more recent VLT observations that astronomers spotted the first hints of a signal corresponding to an object with a five-day orbit. As the signal was so weak, the team had to conduct follow-up observations with ESPRESSO to confirm that it was due to a planet, and not simply a result of changes in the star itself.

“After obtaining new observations, we were able to confirm this signal as a new planet candidate,” Faria says. “I was excited by the challenge of detecting such a small signal and, by doing so, discovering an exoplanet so close to Earth.”

At just a quarter of the mass of Earth, Proxima d is the lightest exoplanet ever measured using the radial velocity technique, surpassing a planet recently discovered in the L 98-59 planetary system. The technique works by picking up tiny wobbles in the motion of a star created by an orbiting planet’s gravitational pull. The effect of Proxima d’s gravity is so small that it only causes Proxima Centauri to move back and forth at around 40 centimetres per second (1.44 kilometres per hour).

“This achievement is extremely important,” says Pedro Figueira, ESPRESSO instrument scientist at ESO in Chile. “It shows that the radial velocity technique has the potential to unveil a population of light planets, like our own, that are expected to be the most abundant in our galaxy and that can potentially host life as we know it.”

“This result clearly shows what ESPRESSO is capable of and makes me wonder about what it will be able to find in the future,” Faria adds.

ESPRESSO’s search for other worlds will be complemented by ESO’s Extremely Large Telescope (ELT), currently under construction in the Atacama Desert, which will be crucial to discovering and studying many more planets around nearby stars.

Story Source:

Materials provided by ESO. Note: Content may be edited for style and length.

Detailed in a new study for the journal Nature, funded by the Engineering and Physical Sciences Research Council (EPSRC), part of UK Research and Innovation, and the Royal Society, the results give the first evidence of a process in ferroelectric materials comparable to the Dzyaloshinskii-Moriya interaction in ferromagnets. This particular interaction plays a pivotal role in stabilising topological magnetic structures, such as skyrmions, and it might be crucial for potential new electronic technologies exploiting their electrical analogues.

Bulk ferroelectric crystals have been used for many years in a range of technologies including sonar, audio transducers and actuators. All these technologies exploit the intrinsic electric dipoles and their inter-relationship between the material’s crystal structure and applied fields.

For this study, the scientists created a thin film of the ferroelectric lead titanate sandwiched between layers of the ferromagnet strontium ruthenate, each about 4 nanometres thick — only twice the thickness of a single strand of DNA.

While the atoms of the two materials form a single continuous crystal structure, in the ferroelectric lead titanate layer the electric polarisation would normally form multiple ‘domains’, like a honeycomb. These domains can only be observed using state-of-the-art transmission electron microscopy and x-ray scattering.

But when the University of Warwick team examined the structure of the combined layers, they saw that the domains in the lead titanate were a complex topological structure of lines of vortexes, spinning alternately in different directions.

Almost identical behaviour has also been seen in ferromagnets where it is known to be generated by the Dzyaloshinskii-Moriya interaction (DMi).

Lead author Professor Marin Alexe of the University of Warwick Department of Physics said: “If you look at how these characteristics scale down, the difference between ferromagnetism and ferroelectricity becomes less and less important. It might be that they will merge at some point in one unique material. This could be artificial and combine very small ferromagnets and ferroelectrics to take advantage of these topological features. It’s very clear to me that we are at the tip of the iceberg as far as where this research is going to go.”

Co-author Dorin Rusu, a postgraduate student at the University of Warwick, said: “Realising that in ferroelectrics dipolar textures that mimic their magnetic counterpart to such a degree ensures further research into the fundamental physics that drives such similarities. This result is not a trivial matter when you consider the difference in the origin and strengths of the electric and magnetic fields.”

The existence of these vortexes had previously been theorised, but it took the use of cutting-edge transmission electron microscopes at the University of Warwick, as well as the use of synchrotrons at four other facilities, to accurately observe them. These techniques allowed the scientists to measure the position of every atom to a high degree of certainty.

Co-author Professor Ana Sanchez said: “Electron microscopy is a game-changing technique in understanding these topological structures. It is the key tool in revealing the ins and outs of these novel materials, using a subatomic beam of electrons to generate images of internal structure.”

Co-author Professor Thomas Hase added: “Accessing high end facilities across UK, Europe and US has been critical for this particular research.”

Story Source:

Materials provided by University of Warwick. Note: Content may be edited for style and length.

The research, recently published in the journal Cell, reveals the immune mechanisms and significant benefits of vaccines being delivered directly into the respiratory tract, rather than by traditional injection.

Because inhaled vaccines target the lungs and upper airways where respiratory viruses first enter the body, they are far more effective at inducing a protective immune response, the researchers report.

The reported preclinical study, which was conducted on animal models, has provided the critical proof of concept to enable a Phase 1 clinical trial that is currently under way to evaluate inhaled aerosol vaccines in healthy adults who had already received two doses of a COVID mRNA vaccine.

The tested COVID vaccine strategy was built upon a robust tuberculosis vaccine research program established by Zhou Xing, a co-lead author of the new study and a professor at the McMaster Immunology Research Centre and Department of Medicine.

“What we’ve discovered from many years’ research is that the vaccine delivered into the lung induces all-around protective respiratory mucosal immunity, a property that the injected vaccine is lacking,” Xing says.

Currently authorized COVID vaccines are all injected.

“We wanted, first and foremost, to design a vaccine that would work well against any variant,” explains the study’s co-lead author Matthew Miller, an associate professor at McMaster’s Michael G. DeGroote Institute for Infectious Disease Research.

The McMaster COVID vaccine represents one of only a handful developed in Canada. The urgent work is a critical mission of Canada’s Global Nexus for Pandemics and Biological Threats, which is based at McMaster.

Researchers compared two types of adenovirus platforms for the vaccine. The viruses serve as vectors that can deliver vaccine directly to the lungs without causing illness themselves.

“We can remain ahead of the virus with our vaccine strategy,” says Miller. “Current vaccines are limited because they will need to be updated and will always be chasing the virus.”

Both types of the new McMaster vaccine are effective against highly transmissible variants because they are designed to target three parts of the virus, including two that are highly conserved among coronaviruses and do not mutate as quickly as spike. All COVID vaccines currently approved in Canada target only the spike protein, which has shown a remarkable ability to mutate.

“This vaccine might also provide pre-emptive protection against a future pandemic, and that’s really important because as we’ve seen during this pandemic — and as we saw in 2009 with the swine flu — even when we are able to rapidly make a vaccine for a pandemic virus, it’s already way too late. Millions of people died, even though we were able to make a vaccine in record time,” says Miller.

“We have revealed in our report that besides neutralizing antibodies and T cell immunity, the vaccine delivered into the lungs stimulates a unique form of immunity known as trained innate immunity, which is able to provide very broad protection against many lung pathogens besides SARS-CoV-2,” Xing adds.

In additional to being needle and pain-free, an inhaled vaccine is so efficient at targeting the lungs and upper airways that it can achieve maximum protection with a small fraction of the dose of current vaccines — possibly as little as 1 per cent — meaning a single batch of vaccine could go 100 times further, the researchers say.

“This pandemic has shown us that vaccine supply can be a huge challenge. Demonstrating that this alternative delivery method can significantly extend vaccine supply could be a game changer, particularly in a pandemic setting,” says Brian Lichty, an associate professor in the Department of Medicine who co-led the preclinical study along with Miller, Xing and the senior trainees Sam Afkhami and Michael D’Agostino, who are the joint first authors of the study.

The vaccines were manufactured at the Robert E. Fitzhenry Vector Laboratory at McMaster University.

The research is funded by a CIHR COVID-19 Rapid Response grant.

Story Source:

Materials provided by McMaster University. Original written by Michelle Donovan. Note: Content may be edited for style and length.

Research into natural products has become a crucial part of drug discovery. Natural products have exhibited promising specificity and efficacy when used against a variety of pathogens, including viruses. For instance, an organic compound called neoechinulin B, isolated from the fungus Eurotium rubrum, has demonstrated antiviral activity against hepatitis C virus (HCV). However, the isolation of such compounds from natural sources can get quite tedious and expensive. Yet, the attempts to synthetically synthesize it seem to be very scarce.

Thus, a group of scientists from across Japan rose to the occasion and embarked on a mission: To discover a simple route for synthesizing neoechinulin B under laboratory conditions. The team included Prof. Kouji Kuramochi and Dr. Koichi Watashi from Tokyo University of Science, along with Dr. Hirofumi Ohashi, Dr. Shusuke Tomoshige, Dr. Kenji Ohgane, and Dr. Shinji Kamisuki from the National Institute of Infectious Diseases, Tohoku University, Ochanomizu University, and Azabu University, respectively. Their findings were recently published in the Journal of Natural Products.

Commenting on their strategy, Prof. Kuramochi, the lead author of the study, says: “We designed a streamlined two-step synthesis strategy to obtain diketopiperazine scaffold of neoechinulin B. The process involved the base-induced coupling of available piperazine-2,5-dione derivative was aldehydes. The coupled products were then treated with a commercial reagent called tetra-n-butylammonium fluoride (TBAF) which gave us neoechinulin B and its 16 other derivatives.”

To ascertain the efficacy of their products, the team tested the antiviral activity of neoechinulin B and its derivatives against different positive-strand RNA viruses, such as HCV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They found that some derivatives showed anti-HCV activity with minimal cell toxicity, while others showed anti-SARS-CoV-2. Moreover, six derivatives exhibited both strong anti-HCV and SARS-CoV-2.

Further studies by the research team uncovered that neoechinulin B and one derivative can reduced the transcriptional activity of liver X receptors (LXRs). This subsequently disrupts the formation of double-membrane vesicles (DMV), which are the sites where viral RNA replication occur. This process results in reduced viral replication in the infected cells.

Along with the 17 active compounds, the scientists also produced three other compounds which, while structurally related to the others, possessed none of the antiviral properties. Further investigation into their molecular structure revealed that inactive compounds were missing the exomethylene moiety which is the key to the antiviral activities of neoechinulin B and its 16 derivatives against HCV and SARS-CoV-2.

The team believes that the insights from this research could be used as a framework for the development of new broad-spectrum antiviral drugs. The study also solidifies the fact that natural products can act as promising lead compounds for the development of antiviral drugs. “The skeleton of neoechinulin B is simple, but only one chemical synthesis method has been reported in the past. Our research presented a simple and viable method for obtaining promising antiviral compounds bringing us one step closer to its practical application,” concludes Prof. Kuramochi.

Story Source:

Materials provided by Tokyo University of Science. Note: Content may be edited for style and length.